Aside from the study by Boxley et al., there is a dearth of information on prostate cancer BM in patients with prior exposure to second-generation androgen receptor-signaling inhibitors, such as abiraterone or enzalutamide, which have become the most used group of agents for the treatment of advanced prostate cancer over the last decade [5]. This evidence concerns the gene AR and Familial prostate cancer.